Citadel Fine Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
- Paid Up Capital ₹ 2.20 M
- Company Age 58 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 11.22 Cr
- Revenue Growth 6.06%
- Profit Growth -88.63%
- Ebitda -56.20%
- Net Worth 0.38%
- Total Assets 1.29%
About Citadel Fine Pharmaceuticals
Citadel Fine Pharmaceuticals Private Limited (CFPPL) was founded in India on 06 August 1966 and has a glorious history of 58 years and six months.Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 2.20 M.
The company has closed loans amounting to ₹11.22 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ramkumar Anekar, Rajiv Krishnamurthy, Ranjan Machina, and One other member serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231TN1966PTC005441
- Company No.
005441
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Aug 1966
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Citadel Fine Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramkumar Anekar  | Director | 05-Oct-2005 | Current |
| Rajiv Krishnamurthy | Director | 05-Oct-2005 | Current |
| Ranjan Machina | Director | 21-Jun-1996 | Current |
| Ramesh Krishnamurthy | Director | 01-Feb-1988 | Current |
Financial Performance of Citadel Fine Pharmaceuticals.
Citadel Fine Pharmaceuticals Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 6.06% increase. The company also saw a substantial fall in profitability, with a 88.63% decrease in profit. The company's net worth moved up by a moderate rise of 0.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Citadel Fine Pharmaceuticals?
In 2020, Citadel Fine Pharmaceuticals had a promoter holding of 13.14% and a public holding of 86.86%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Citadel Aurobindo Biotech LimitedRajiv Krishnamurthy is a mutual person
Anekar Agrotech Private LimitedRamkumar Anekar is a mutual person
- Pranam Health Private Limited
Ramesh Krishnamurthy is a mutual person
Charges (Loans)
₹0
₹112.16 M
Charges Breakdown by Lending Institutions
- State Bank Of India : 11.18 Cr
- The Karnataka Bank Ltd : 0.03 Cr
- The Karnaka Bank Ltd : 0.01 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Apr 2003 | State Bank Of India | ₹2.00 Cr | Satisfied |
| 15 Mar 1997 | State Bank Of India | ₹1.92 Cr | Satisfied |
| 25 Feb 1995 | State Bank Of India | ₹2.10 Cr | Satisfied |
| 30 Mar 1992 | State Bank Of India | ₹1.80 Cr | Satisfied |
| 26 Apr 1990 | State Bank Of India | ₹1.13 Cr | Satisfied |
How Many Employees Work at Citadel Fine Pharmaceuticals?
Unlock and access historical data on people associated with Citadel Fine Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Citadel Fine Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Citadel Fine Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
